Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
5.56
+0.72 (14.88%)
At close: Dec 5, 2025, 4:00 PM EST
5.67
+0.11 (1.97%)
After-hours: Dec 5, 2025, 7:56 PM EST
Immix Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 12.14 | 11.38 | 7.41 | 4.02 | 1.23 | 0.21 | |
| Research & Development | 11.91 | 11.29 | 8.74 | 4.2 | 0.13 | 0.25 | |
| Operating Expenses | 24.05 | 22.67 | 16.14 | 8.22 | 1.35 | 0.45 | |
| Operating Income | -24.05 | -22.67 | -16.14 | -8.22 | -1.35 | -0.45 | |
| Interest Expense | - | - | - | -0 | -0.18 | -0.1 | |
| Interest & Investment Income | 0.52 | 1.02 | 0.57 | - | - | - | |
| Other Non Operating Income (Expenses) | - | - | - | - | -22.76 | -0.57 | |
| EBT Excluding Unusual Items | -23.53 | -21.66 | -15.57 | -8.22 | -24.29 | -1.13 | |
| Other Unusual Items | - | - | - | - | -0.09 | - | |
| Pretax Income | -23.53 | -21.66 | -15.57 | -8.22 | -24.38 | -1.13 | |
| Income Tax Expense | 0.04 | 0.04 | 0.03 | 0.01 | 0.01 | 0.02 | |
| Earnings From Continuing Operations | -23.56 | -21.7 | -15.6 | -8.23 | -24.38 | -1.15 | |
| Minority Interest in Earnings | - | 0.08 | 0.17 | - | - | - | |
| Net Income | -23.56 | -21.61 | -15.43 | -8.23 | -24.38 | -1.15 | |
| Net Income to Common | -23.56 | -21.61 | -15.43 | -8.23 | -24.38 | -1.15 | |
| Shares Outstanding (Basic) | 30 | 28 | 17 | 14 | 4 | 3 | |
| Shares Outstanding (Diluted) | 30 | 28 | 17 | 14 | 4 | 3 | |
| Shares Change (YoY) | 15.04% | 63.11% | 24.87% | 278.13% | 8.82% | - | |
| EPS (Basic) | -0.78 | -0.76 | -0.89 | -0.59 | -6.64 | -0.34 | |
| EPS (Diluted) | -0.78 | -0.76 | -0.89 | -0.59 | -6.64 | -0.34 | |
| Free Cash Flow | -15.45 | -15.77 | -11.42 | -7.41 | -1.59 | -0.4 | |
| Free Cash Flow Per Share | -0.51 | -0.56 | -0.66 | -0.53 | -0.43 | -0.12 | |
| EBITDA | -23.84 | -22.64 | -16.14 | -8.22 | -1.35 | -0.45 | |
| D&A For EBITDA | 0.21 | 0.03 | 0.01 | 0 | 0 | 0 | |
| EBIT | -24.05 | -22.67 | -16.14 | -8.22 | -1.35 | -0.45 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.